• 1
    Takeda T, Morimoto N, Kinukawa N, Nagamine R, Shutou T, Tashiro N. Factors affecting depression and anxiety in female Japanese patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2000; 18: 735738.
  • 2
    Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin. Rheumatol. 2006; 25: 448452.
  • 3
    Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: A systematic review. Semin. Arthritis Rheum. 2006; 36: 182188.
  • 4
    Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 2005; 130136.
  • 5
    Akar S, Akkoç N. Epidemiology of rheumatoid arthritis. Turk. Klin. J. Int. Med. Sci. 2006; 6: 16 (in Turkish).
  • 6
    Fresko İ. Etiology and pathogenesis of rheumatoid arthritis. Turk. Klin. J. Int. Med. Sci. 2006; 2: 711 (in Turkish).
  • 7
    Hatemi G, Yazici H. Clinical features of rheumatoid arthritis. Turk. Klin. J. Int. Med. Sci. 2006; 2: 1217 (in Turkish).
  • 8
    Işik A, Koca SS, Öztürk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26: 872878.
  • 9
    Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: A systematic review of the literature with meta-analysis. Psychosom. Med. 2002; 64: 5260.
  • 10
    Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J. Rheumatol. 2005; 32: 10131019.
  • 11
    Chandrana PC, Eals M, Steingart AB, Bellamy N, Allen S. The detection of psychiatric morbidity and associated factors in patients with rheumatoid arthritis. Can. J. Psychiatry 1987; 32: 356361.
  • 12
    Söderlin MK, Hakala M, Nieminen P. Anxiety and depression in a community-based rheumatoid arthritis population. Scand. J. Rheumatol. 2000; 29: 177183.
  • 13
    Covic T, Tyson G, Spencer S, Howe G. Depression in rheumatoid arthritis patients: Demographic, clinical, and psychological predictors. J. Psychosom. Res. 2006; 60: 469476.
  • 14
    El-Miedany YM, El-Rasheed AH. Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine 2002; 69: 300306.
  • 15
    Dickens C, Jackson J, Tomenson B, Hay E, Creed F. Association of depression and rheumatoid arthritis. Psychosomatics 2003; 44: 209215.
  • 16
    Abdel-Nasser AM, Abd El-Azim S, Taal E, El-Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: An analysis of their occurrence and determinants. Br. J. Rheumatol. 1998; 37: 391397.
  • 17
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press, 1994.
  • 18
    Löwe B, Willand L, Eich W et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom. Med. 2004; 66: 395402.
  • 19
    Murphy H, Dickens C, Creed F, Bernstein R. Depression, illness perception and coping in rheumatoid arthritis. J. Psychosom. Res. 1999; 46: 155164.
  • 20
    Piccinni A, Maser JD, Bazzichi L et al. Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis. Compr. Psychiatry 2006; 47: 201208.
  • 21
    Bazzichi L, Maser J, Piccinni A et al. Quality of life in rheumatoid arthritis: Impact of disability and lifetime depressive spectrum symptomatology. Clin. Exp. Rheumatol. 2005; 23: 783788.
  • 22
    Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR, Allard S. A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: Preventing psychological and physical morbidity. Pain 2001; 89: 275283.
  • 23
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315324.
  • 24
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV). Washington, DC: American Psychiatric Press, 1997.
  • 25
    Fries J, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J. Rheumatol. 1982; 9: 789793.
  • 26
    Prevoo ML, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 4448.
  • 27
    Regier DA, Farmer ME, Rae DS et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment area Study. Acta Psychiatr. Scand. 1993; 88: 3547.
  • 28
    Vicente B, Kohn R, Rioseco P, Saldivia S, Baker C, Torres S. Population prevalence of psychiatric disorders in Chile: 6-month and 1-month rates. Br. J. Psychiatry 2004; 84: 299305.
  • 29
    Bijl RV, Ravelli A, Van Zessen G. Prevalence of psychiatric disorder in the general population: Results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc. Psychiatry Psychiatr. Epidemiol. 1998; 33: 587595.
  • 30
    Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry 2006; 67: 12191225.
  • 31
    Frank RG, Beck NC, Parker JC et al. Depression in rheumatoid arthritis. J. Rheumatol. 1988; 15: 920925.
  • 32
    Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J. Rheumatol. 1993; 20: 790796.
  • 33
    Taylor PC. Anti-TNF-α therapy for rheumatoid arthritis: An update. Intern. Med. 2003; 42: 1520.
  • 34
    Klimiuk PA, Sierakowski S, Latosiewicz R et al. Circulating tumour necrosis factor α and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann. Rheum. Dis. 2003; 62: 472475.
  • 35
    Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay C. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003; 170: 429433.
  • 36
    O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychosom. Res. 2007; 41: 326331.
  • 37
    Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M. Interferon-α induced depressive symptoms are related to changes in the cytokine network but not to cortizol. J. Psychosom. Res. 2007; 62: 207214.
  • 38
    Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J. Psychosom. Res. 2007; 62: 18.
  • 39
    Pitsavos C, Panagiotakos DB, Papagergiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: The ATTICA study. Atherosclerosis 2006; 185: 320326.
  • 40
    Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1 β, interleukin-6, and tumor necrosis factor-α: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000; 22: 566580.
  • 41
    Reynolds JL, Ignatowski TA, Sud R, Spengler RN. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-α production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005; 133: 519531.